A Proteomics Signature of Mild Hypospadias: A Pilot Study

Coriness Piñeyro-Ruiz1, Horacio Serrano2,3,4, Inmaculada Jorge5,6, Eric Miranda-Valentin2,3, Marcos R. Pérez-Brayfield1, Emilio Camafeita5,6, Raquel Mesa6, Jesús Vázquez5,6 and Juan Carlos Jorge1

1 Department of Anatomy and Neurobiology, School of Medicine, University of Puerto Rico, San Juan, PR, United States, 2 Department of Internal Medicine, School of Medicine, University of Puerto Rico, San Juan, PR, United States, 3 Clinical Proteomics Laboratory, Internal Medicine Department, Comprehensive Cancer Center (CCC)-Medical Sciences Campus (MSC)-University of Puerto Rico (UPR), San Juan, PR, United States, 4 Department of Biochemistry, School of Medicine, University of Puerto Rico, San Juan, PR, United States, 5 Cardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, 6 Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, 7 Department of Surgery, Urology Section, School of Medicine, University of Puerto Rico, San Juan, PR, United States

Background and Objective: Mild hypospadias is a birth congenital condition characterized by the relocation of the male urethral meatus from its typical anatomical position near the tip of the glans penis, to a lower ventral position up to the brim of the glans corona, which can also be accompanied by foreskin ventral deficiency. For the most part, a limited number of cases have known etiology. We have followed a high-throughput proteomics approach to study the proteome in mild hypospadias patients.

Methods: Foreskin samples from patients with mild hypospadias were collected during urethroplasty, while control samples were collected during elective circumcision (n = 5/group). A high-throughput, quantitative proteomics approach based on multiplexed peptide stable isotope labeling (SIL) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was used to ascertain protein abundance changes in hypospadias patients when compared to control samples.

Results: A total of 4,815 proteins were quantitated (2,522 with at least two unique peptides). One hundred and thirty-three proteins from patients with mild hypospadias showed significant abundance changes with respect to control samples, where 38 proteins were increased, and 95 proteins were decreased. Unbiased functional biological analysis revealed that both mitochondrial energy production and apoptotic signaling pathways were enriched in mild hypospadias.

Conclusions: This first comprehensive proteomics characterization of mild hypospadias shows molecular changes associated with essential cellular processes related to energy production and apoptosis. Further evaluation of the proteome may expand the search of novel candidates in the etiology of mild hypospadias and could also lead to the identification of biomarkers for this congenital urogenital condition.

Keywords: quantitative proteomics, etiology, proteomics, hypospadias, liquid chromatography-tandem mass spectrometry (LC-MS/MS)
INTRODUCTION

Hypospadias is characterized by the localization of the urethral opening at any anatomical position on the ventral-medial side of the penis rather than near the tip of the glans. Its prevalence is ~21/10,000 live births (1–7). The most common type of this congenital urogenital condition is mild hypospadias (1st degree, anterior or Type I), comprising ~70% of cases, followed by moderate hypospadias (2nd degree, middle, or Type II) and severe hypospadias (3rd degree, posterior or Type III) with the remaining 30% (5, 8–11).

The formation of the male external genitalia is both a hormone-dependent and a hormone-independent multistep developmental event that spans embryonic and fetal periods. The androgen receptor (AR), activating transcription factor 3 (ATF3), estrogen receptor 1 and 2 (ESR1 and ESR2), steroid-5-alpha-reductase 2 (SRD5A2), hydroxysteroid (17-beta) dehydrogenase 3 (HSD17B3), hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta isomerase 1 (HSD3B1), stAR-related lipid transfer domain containing 3 (STAR3D), and mastermind like domain containing 1 (MAML1) are some of the genes that have been identified and associated with hypospadias (8, 12–25). In fact, molecular differences have been found at the gene, mRNA, and protein levels according to severity. Polymorphisms, mutations, and epigenetic changes in the AR, CYR61, HSD17B3, HSD3B1, MAML1, SRD5A2, and STAR3D have been associated to hypospadias risk in severe types of hypospadias that have not been found in mild hypospadias (26–30). Some examples of these include reduced AR gene methylation (31) and increased GGN or CAG repeat sequence of the AR gene [(32, 33); respectively]. Allele variations and single nucleotide polymorphisms (SNPs) of the SRD5A2 have also been associated with hypospadias risk (13, 27, 29, 34). Similarly, upregulation of ATF3 in preputial tissue from hypospadiac boys has been reported (30, 35–37). SNPs and haplotypes in ESR1 (17, 38, 39) and longer variants of (CA)n polymorphism in ESR2 (40) have been identified and associated with hypospadias. At the mRNA and protein level, significant changes as severity increases have been observed in AR, CYR61, ATF3, and CTGF, some of which are estrogen-responsive genes (30, 41). In terms of downstream products, we found lower concentrations of aspartate in moderate and severe hypospadias but not in mild hypospadias (42). This finding is of interest as aspartate modulates steroidogenesis in Leydig cells (43–45). In addition, it has been shown that aspartate increases testosterone, dihydrotestosterone (DHT), luteinizing hormone (LH), and gonadotropin-releasing hormone (GnRH) levels, as well as stAR mRNA and protein expression levels and AR protein expression levels (46–50).

Despite these associations with hormone-dependent pathways, the etiology of hypospadias remains elusive. In addition to steroid signaling, the development of the male external genitalia involves cell migration, differentiation, and proliferation, patterning, and apoptosis during development, all of which demand high energy inputs. For instance, luminalization of the glandular urethra is achieved through apoptosis in the solid epithelial cord at the tip of the glans (51). Therefore, we hypothesized that disruption of proteins with key cellular roles previously ascribed to embryonic and fetal development would be apparent in the proteome of mild hypospadias. We found that cellular energy and apoptotic processes are disrupted in mild forms of this congenital condition.

MATERIALS AND METHODS

Human Tissue Samples

This study was approved by the Institutional Review Board (IRB) under the Human Research Subjects Protection Office (HRSCO) at the University of Puerto Rico, Medical Sciences Campus. Parents of children undergoing urethroplasty and boys scheduled for elective circumcision were recruited at the HIMA San Pablo Hospital, Caguas, Puerto Rico. Hypospadias was assessed by Marcos Raymond Pérez-Brayfield, MD (pediatric urologist, Faculty in Surgery, Urology Section, School of Medicine, UPR). Informed consent was obtained from legal parents or guardians. Foreskin samples were collected from boys with non-comorbid mild hypospadias (also known as 1st degree, anterior or Type I hypospadias: n = 5) and elective circumcision (n = 5) between the ages of 5–28 months of age.

Mild hypospadias cases were confirmed during urethroplasty and included two glandular, one coronal, and two subcoronal cases after penile degloving and chordee release whenever present. Table 1 shows the age of the patient and the location of the urethral meatus. Given that this study did not control for the age of the patient at the time of the urethroplasty procedure for mild hypospadias cases, the age distribution in this patient cohort was not normally distributed. Mann-Whitney test revealed a significant age difference between experimental groups (p = 0.02; see Discussion for further details). Samples were obtained from both lateral and dorsal inner foreskin tissue, which is mostly comprised of mucous membrane. Samples with suggestive clinical changes of balanitis xerotica obliterans (B XO) were excluded from the study.

Preparation of Protein Extracts

One hundred milligrams of wet foreskin tissue were weighed and homogenized with a tissue tearor in 1.0 mL of Lysis Buffer (50 mM Tris, 10 mM DTT, and 1% SDS pH 6.8). Samples were incubated for 5 min at 97°C with shaking (600 rpm, Eppendorf

| TABLE 1 | Clinical characteristics of patients at the time of urethroplasty. |
|----------|---------------------------------------------------------------|
| Patient  | Age (months) | Urethral meatus location |
| Controls |                  |                             |
| C1       | 8               | Typical                     |
| C2       | 24              | Typical                     |
| C3       | 28              | Typical                     |
| C4       | 28              | Typical                     |
| C5       | 11              | Typical                     |
| Mild hypospadias | H1 22 Glandular |                 |
| H2       | 6               | Subcoronal                  |
| H3       | 5               | Glandular                   |
| H4       | 6               | Coronal                     |
| H5       | 6               | Subcoronal                  |
Thermomixer), and thereafter incubated overnight in rotator at 4°C. Homogenates were centrifuged for 5 min at 13,000 rpm, and the supernatant was collected. Protein concentration in the protein extracts was measured using the RC DC Protein Assay Kit II (Bio-Rad, USA) following the manufacturer’s instructions.

**Protein Digestion and Peptide Labeling**

Protein extracts (100 µg) were concentrated on 30 K Filter-Aided Sample Preparation (FASP) filters (Expedeon). After washing with denaturing buffer (8 M urea in 100 mM Tris-HCl pH 8.5) at 10,000 rpm for 15 min, free thiol groups were alkylated by incubation with 50 mM iodoacetamide 30 min at room temperature in the dark. Then the filters were washed with denaturing buffer followed by washing with trypsin digestion buffer (50 mM ammonium bicarbonate pH 8.8). Protein samples were digested overnight at 37°C with sequencing grade trypsin (Promega, Madison, WI, USA) at 1:40 (w/w) trypsin: protein ratio in digestion buffer. The resulting tryptic peptides from each sample were recovered by centrifugation at 10,000 rpm for 5 min after the addition of 40 µl of trypsin digestion buffer after which 50 µl of 500 mM NaCl was added and the filters centrifuged for 15 min at 10,000 rpm. Trifluoroacetic acid was added to a final concentration of 1%, and the peptides were desalted on C18 Oasis HLB extraction cartridges (Waters Corporation, Milford, MA, USA) and dried-down. Peptide labeling was performed using a 10-plex TMT kit (Tandem Mass Tag, Thermo Scientific, USA) according to the manufacturer’s instructions, and desalted onto Oasis C18 cartridges before analysis by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

**Protein Identification by Liquid Chromatography-Tandem Mass Spectrometry Analysis**

LC-MS/MS was performed using a nano-HPLC Easy nLC 1,000 chromatograph coupled to a Q-Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Scientific). Peptides were loaded onto a C18 RP nano-precolumn (75 µm I.D. and 2 cm, Acclaim PepMap 100, Thermo Scientific), and separated on an analytical C18 nano-column (75 µm I.D. and 50 cm, Acclaim PepMap 100) using a continuous gradient consisting of 8–30% B for 60 min and 30–90% B for 2 min (B = 90% ACN, 0.1% formic acid) at 200 nL/min. The chromatographic run acquired an FT-resolution spectrum (140,000 resolution) in the 390-1,500 m/z range, followed by data-dependent MS/MS spectra of the 15 most intense parent ions. The normalized HCD collision energy was set to 30%, and the parent ion mass isolation width was 1.5 Da.

Peptides were identified from MS/MS spectra using the SEQUEST HT algorithm integrated with Proteome Discoverer 2.1 (Thermo Scientific). MS/MS scans were matched against a human protein database (UniProt 2017_12_19 Release). Parameters were selected as follows: two trypsin missed cleavages maximum, 800 ppm precursor mass tolerance and 0.02 Da fragment mass tolerance. Cys carbamidomethylation, N-terminal TMT labeling, and Lys TMT labeling were chosen as fixed modifications, while Met oxidation was considered a dynamic modification. For peptide false discovery rate (FDR) assessment using the refined method (52, 53), MS/MS spectra were searched against the corresponding inverted human database.

**Quantification of Protein Abundance Changes**

Quantitative information was extracted from the intensity of the TMT reporter ions in MS/MS spectra. Protein abundance changes were assessed based on the Weighted Scan-Peptide-Protein (WSPP) statistical model (54) under the SanXoT software package (55). This model provides the standardized variable Zq, which is defined as the mean-corrected log2-ratio expressed in units of standard deviation at the protein level. Thus, Zq values were calculated for each sample, both mild hypospadias, and control samples, with respect to a weighted average of control samples. The study design is depicted in Figure 1.

**Statistical Analyses**

Statistical comparison between hypospadias and control group Zq values was performed by Student’s t-test. A p-value < 0.05 was considered significant. The MetaboAnalyst (56) online platform was used with Zq values to perform multivariate statistical analyses, including principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA).

**Functional Enrichment Analysis**

The STRING database (http://string-db.org), version 11.0 (57), was used for functional enrichment analysis with proteins found significantly decreased (95 proteins) or increased (38 proteins) in the hypospadias group. A low protein-protein interaction (PPI) enrichment p-value indicates that the nodes are not random and that the observed number of edges is significant. A 5% FDR cutoff was used to evaluate significant functional category enrichment. Supplementary Table 1 details accession numbers, gene, and protein names for these proteins.

**Validation of Cytochrome C by ELISA**

Cytochrome C was detected and quantified by enzyme-linked immunosorbent assay (ELISA; n = 10 controls and n = 8 mild hypospadias). Test results were submitted to the Mann-Whitney U-test statistical analysis. Human Cytochrome C Platinum ELISA (Thermo Fisher Scientific, Waltham, MA) was used for quantitative detection following the protocol provided by the manufacturer.

**RESULTS**

**Proteomic Profile of Mild Hypospadias**

A multiplexed, quantitative proteomics approach based on 10-plex TMT labeling and LC-MS/MS analysis was employed to identify and quantify proteins of foreskin tissue from mild hypospadias and control samples (n = 5/group). A total of 2,522 proteins were identified and quantified with more than one unique peptide. Multivariate analyses revealed differences between the proteome of mild hypospadias samples when compared to control samples. Principal component analysis showed that control samples displayed a wide distribution, whereas samples from mild hypospadias patients were similar amongst each other. Components were explained by principal component (PC) 1 with a 29.2% variance and PC 2 with a 18.1%...
Piñeyro-Ruiz et al. Proteomics Signature in Mild Hypospadias

FIGURE 1 | Proteomics study design. Foreskin samples were collected during scheduled urethroplasty from patients with mild hypospadias (n = 5) or from individuals submitted to a circumcision procedure (control group, n = 5). One-hundred milligrams of foreskin samples from each patient were homogenized and proteins extracted from tissue. A total of 100 µg of protein was processed per sample. Protein extracts were digested with trypsin using the FASP technology. Subsequently, peptide samples were labeled using a 10-plex TMT kit. Each sample was labeled with a specific TMT mass tag. After labeling, samples were pooled and separated into five fractions using high pH reversed-phase peptide fractionation. Peptides were resuspended in 0.1% formic acid and analyzed by LC-MS/MS. Upon fragmentation, the specific reporter ion released from each of the 10 mass tags shows in the low-mass region of the MS/MS spectrum. The intensity of this reporter ion was used to measure relative peptide abundance levels among samples, from which relative protein abundance between control and mild hypospadias cases was inferred (see text for details).

variance. Figure 2A depicts PC1 and PC2 components with 95% confidence ellipses for control and mild hypospadias samples. Furthermore, PLS-DA showed a marked separation between control and mild hypospadias groups. Partial least squares (PLS) 1 contributed 17.5%, whereas PLS2 carried 21.9% of the total variance. Figure 2B shows the separation between control and mild hypospadias groups with 95% confidence ellipses. One hundred thirty-three proteins were identified with significant changes in protein abundance in mild hypospadias samples in comparison to control samples at 1% FDR (available at PeptideAtlas repository). Specifically, 95 proteins were found decreased (Figure 3), and 38 proteins were increased (Figure 4) in mild hypospadias when compared to control samples. Supplementary Table 1 details accession numbers, gene, and protein names for these proteins.

Enriched Biological Processes in Mild Hypospadias

We performed an unbiased functional enrichment analysis for proteins showing significantly decreased or increased abundances using STRING network analysis. Interacting proteins were found in both sets of proteins with a PPI enrichment p-value < 1.0e-16. For proteins with decreased levels, 257 Gene Ontology (GO) terms were found significantly enriched (Supplementary Table 2). For proteins with increased levels, 79 GO terms were found significantly enriched (Supplementary Table 3). Within the identified biological processes that were enriched, we observed pathways involving cellular energy processes and apoptotic signaling (Table 2).

Cytochrome C (CYCS) Validation

CYCS is an essential protein in the mitochondrial electron transport chain that also plays key roles in apoptosis through the caspase-dependent apoptosis pathway. Given that biological processes related to cellular energy and apoptotic processes were found significantly enriched in this study, CYCS was selected for validation with ELISA. Significant differences between control and mild hypospadias samples were found (p = 0.0067). Specifically, CYCS was found in lower concentrations (ng/ml) in mild hypospadias (median = 8.86) when compared to control samples (median = 12.56; Figure 5).
DISCUSSION

To the best of our knowledge, this is the first study that has evaluated the proteome in mild hypospadias, which is the most common type of this congenital urogenital condition accounting for nearly 70% of cases. We have analyzed human foreskin samples by using a multiplexed, quantitative proteomics approach based on SIL and LC-MS/MS that has allowed the identification of 2,522 proteins which were identified with two or more unique peptides. Significant differences in protein abundances were identified for 133 proteins. Specifically, 95 proteins were found with significantly decreased protein abundance and 38 with significantly increased protein abundance in mild hypospadias when compared to control samples. It is of interest that unbiased functional enrichment analysis revealed mitochondrial energy production and apoptotic signaling pathways as significantly enriched processes.

Mitochondrial dysfunction has been linked to congenital conditions such as spina bifida, cardiomyopathy, and inborn errors of metabolism (58–60). Our enrichment data, from known and predicted protein-protein interactions, revealed interactions between ADH1A, ADH1B, ATP5J, CYCS, DERA, FH, GPD2,HK1, NDUFAB1, NDUFAB6, NNT, OGDH, PKG1, and SUCLA2 for generation of precursor metabolites and energy; CYCS, FH, GPD2, NDUFAB1, NDUFAB6, NNT, OGDH, and SUCLA2 for cellular respiration; CYCS, GPD2, NDUFAB6, and NDUFAB1 for respiratory electron transport chain; ATP1B1, ATP5J, CYCS, HK1, NDUFAB1, NDUFAB6, OGDH, and PGKI for ATP metabolic process; FH, NNT, OGDH, and SUCLA2 for tricarboxylic acid cycle; ATP5J, HK1, OGDH, and PGKI for ATP biosynthetic process; HK1, OGDH, and PGKI for glycolytic process; and GOT2, GPD2, and PGKI for gluconeogenesis, among other which indirectly contribute to cellular energy processes such as glucose metabolic process, fatty acid metabolic process, and fumarate metabolic process.

Embryonic development demands high energy inputs to carry out essential processes such as cellular differentiation, cell migration, proliferation, and patterning processes. Early during the embryonic period, the major source of energy is glycolysis. As the embryo develops, cells produce energy from the three major processes of energy production in eukaryotic cells: glycolysis, Krebs cycle, and the electron transport chain (61). Thus, it is not surprising that the dysregulation of proteins involved in the production of cellular energy demands has been linked to congenital conditions, as shown here. For instance, PGK, NNT, SUCLA2, and FH have been linked to inherited disorders including, but not limited to, infantile encephalopathy, X-linked inherited disorders, myopathies, and neural tube defects (62–66). Programmed cell death is also an energy-dependent process, and, as reported here, the intrinsic apoptotic signaling pathway (67, 68) was disrupted in mild hypospadias samples. Taken together, our results may present a new molecular research strategy to study mild hypospadias, although further research on the involvement of mitochondrial dysfunction in this congenital condition may provide promising venues for future scientific inquiry.

Furthermore, apoptosis plays a key role during the development of the male genitalia (51, 69, 70). Previous studies have proposed that the suppression of apoptotic-related genes can give rise to hypospadias (71, 72). For instance, reduced apoptosis is observed in finasteride-induced hypospadiac rats through the MAPK/ERK signaling pathway (73). In addition, as confirmed by the presence of apoptotic cells, the luminization...
of the urethra in human embryo specimens is accomplished by apoptosis (51).

Of note, in this study, CYCS was found significantly downregulated in mild hypospadias samples. CYCS is an inner mitochondrial protein with key biological roles in mitochondrial electron transport and apoptosis. Cytochrome C assumes an apoptotic role when released into the cytosol. Suppression or activation of anti- and pro-apoptotic members of the Bcl-2 family leads to altered mitochondrial membrane permeability resulting in the release of CYCS into the cytosol. Once in the cytosol, CYCS binds to Apaf-1, which triggers the activation of caspase-9, which in turn accelerates apoptosis by the activation of other caspases (74). Given the major role of CYCS as a modulator of apoptosis, we analyzed additional samples by ELISA, which revealed a significant downregulation of CYCS in mild hypospadias as compared to control samples. It remains as a challenge for future experiments to determine the time course of such downregulation across development.
FIGURE 4 | Proteins found upregulated in the proteome from mild hypospadias patients. Thirty-eight proteins were found increased between control and mild hypospadias samples. Heatmaps depict protein abundance changes in terms of Zq across samples (C1-C5 for control and H1-H5 for mild hypospadias samples). The magnitude of abundance change (increased (red) or decreased (blue)) is shown according to the color scale on the right.
### TABLE 2 | Enriched functional categories involving cellular energy processes and apoptotic signaling pathways.

| GO term | Description                                                                 | False discovery rate (FDR) | Proteins in gene set                                      |
|---------|------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------|
| GO:0006091 | Generation of precursor metabolites and energy                              | 0.00000326                  | ADH1A, ADH1B, ATP5J, CYCS, FH, GPD2, HK1, NDUFAB1, NNT, OGDH, PGK1, SUCLA2 |
| GO:0045333 | Cellular respiration                                                        | 0.00012                      | CYCS, FH, GPD2, NDUFAB1, NNT, OGDH, SUCLA2             |
| GO:0046034 | ATP metabolic process                                                       | 0.00029                      | ATP1B1, ATP5J, CYCS, HK1, NDUFAB1, OGDH, PGK1         |
| GO:0006099 | Tricarboxylic acid cycle                                                    | 0.00043                      | FH, NNT, OGDH, SUCLA2                                  |
| GO:0006096 | Glycolytic process                                                          | 0.0067                       | HK1, OGDH, PGK1                                       |
| GO:0006094 | Gluconeogenesis                                                             | 0.0089                       | GOT2, GPD2, PGK1                                     |
| GO:0006193 | Intrinsic apoptotic signaling pathway                                        | 0.0206                       | AIFM1, CUL3, CUL4A, CYCS                               |
| GO:0029204 | Respiratory electron transport chain                                         | 0.0149                       | CYCS, GPD2, NDUFAB6, NDUFAB1                           |
| GO:0006754 | ATP biosynthetic process                                                    | 0.0081                       | ATP5J, HK1, OGDH, PGK1                                |
| GO:2000325 | Negative regulation of endothelial cell apoptotic process                   | 0.0078                       | FGA, FGG                                              |
| GO:1902042 | Negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 0.0108                       | FGA, FGG                                              |

**FIGURE 5** | Validation of cytochrome C by ELISA. Cytochrome C was found in significantly lower concentrations in mild hypospadias samples (median = 8.86 ng/ml) in comparison to controls (median = 12.56 ng/ml) samples in agreement with proteomics results. Dashed line represents the median value. Dotted lines represent quartiles; top: 75% percentile and bottom: 25% percentile. ** = p < 0.05. Controls, n = 10; Mild hypospadias, n = 8.

AIFM1, which has also been found downregulated in the hypospadias group, is a pro-apoptotic factor in the caspase-independent pathway, which, in response to apoptotic stimuli, is released from the mitochondrial intermembrane space into the cytosol and to the nucleus (74). Mutations of AIF can lead to severe mitochondrial dysfunction and have been associated with several disorders and neuropathogenesis (75–77). CUL3 and CUL4A, which were also downregulated, are part of the Cullin gene family, the largest ubiquitin ligase family in mammals, which are part of the core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes that mediate the ubiquitination of target proteins and subsequent proteasomal degradation. These proteins participate in the extrinsic apoptotic pathway activated by the tumor necrosis factor (TNF) receptor family through the ubiquitination of caspase-8 (78–80). CUL4A-mediated protein degradation has been reported as essential for the maturation of primary spermatocytes in mouse testis (81). Taken together, the observed downregulation of AIFM1, CUL3, CUL4A, and CYCS in this study warrants further research.

There are a number of limitations to this study. As the first study of the proteome in hypospadias, it is necessary to replicate the results presented here with a larger patient cohort. Owing to the difficulties inherent to obtaining patient tissue samples, the high cost of proteomics analysis, and the limited access to instruments, many clinical proteomics studies are based on relatively small patient cohorts [see, for example, (82–84)]. It is important to validate clinical proteomics results with larger patient cohorts and by using orthogonal techniques like ELISA and Western blot. The validation of Cytochrome C presented here is a first step in this direction. It must be noted, however, that in this study, the limited number of samples is compensated by the application of WSPP as a rigorous statistical model. Second, although the current state of knowledge on the proximal growth of the preputial lamina over the glans penis is most-likely an androgen-dependent effect that is completed during intrauterine development (85), this study cannot address whether the so-called “mini-puberty” in males (86, 87) contributes further to cytoarchitectural changes of foreskin samples so that some of the changes in protein levels observed here could be due, at least in part, to postnatal androgen-dependent effects in foreskin tissue up to 12 months of age. Important to note is that available evidence suggests that human penile growth is androgen-independent from ∼12 months of age up to puberty (87). Given the age range of our patient cohort, we cannot address this question. Nevertheless, in humans, the effects of postnatal cytoarchitectural changes on foreskin protein expression will most likely remain as a vexata quaestio as it is unethical to time urethroplasty.
procedures to address this experimental conundrum. Related to this, the third limitation of this study is the significant age difference between experimental groups. Although it has been noted that histological and morphological changes occur in foreskin tissue during postnatal development (88), such as changes in vasculature, connective tissue, and nervous tissue, for example, we are of the opinion that it is unlikely that such structural changes during development heavily rely on the distinct cellular energy and apoptotic pathways reported here. The fourth limitation of this study is related to the histological origin of foreskin samples, which were mostly comprised of lateral and dorsal foreskin primarily due to the ventral deficiency that characterizes hypospasias. This study cannot rule out the possibility of under- or over-estimating the levels of protein expression because it is not possible to sample the circumferential prepuce in hypospasias. Of interest, the formation of the circumferential prepuce during intrauterine development is an androgen-independent event (89). In fact, future studies on the dependency of androgen signaling for the changes in protein expression levels observed here may provide valuable insights on the timing of embryological events that are affected in hypospasias.

The results reported in this study rely on a multi-step data analysis approach within a carefully designed statistical framework that allows for the identification of proteins, their relative abundances, and the quantitative analysis of whether such abundances significantly differ among experimental groups. It is important to underscore that pathways and protein-protein interactions reported here rely on existing protein databases. These are “predicted” pathways and interactions based on published data from a myriad of biological systems studied with a staggering diversity of experimental approaches. The ones discussed here are based on our own interpretation or previously linked to hypospasias or other congenital conditions.

In conclusion, this first line of proteomics assessment shows a differential proteome profile for mild hypospasias. Proteins related to cellular energy production and apoptotic pathways stand out in this proteomics signature. These pathways may facilitate the search for novel candidates in the etiology of mild hypospasias and may also constitute potential biomarkers for early detection of this congenital urogenital condition.

DATA AVAILABILITY STATEMENT

The datasets generated in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: http://www.peptideatlas.org/PASS/PASS01602.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Human Research Subjects Protection Office (HRSPO) at the University of Puerto Rico, Medical Sciences Campus. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

The study was designed by CP-R, MP-B, and JJ. MP-B performed all surgical procedures and collected all tissue samples. CP-R assisted in sample collection and conducted sample preparation for proteomics experiments under the guidance and expert advice of HS and conducted validation experiments. IJ, EC, RM, and JV developed statistical algorithms and submitted collected samples to proteomic analyses. EM-V assisted in sample preparation and performed statistical analysis for validation experiments. Final analyses, the depiction of data, and writing of the first draft were by CP-R and JJ. All authors participated in the drafting and approval of the final version of the manuscript.

FUNDING

This research was supported by the Research Initiative for Scientific Enhancement (MBRS-RISE) Program Award Number R25GM061838, by the National Institute on Minority Health and Health Disparities of the National Institutes of Health Award Number 8G12MD007600, by the Hispanic Alliance for Clinical and Translational Research of the National Institutes of Health under award number U54GM133807-01A1, and by the Comprehensive Cancer Center of the UPR (a public corporation of the Government of Puerto Rico created in virtue of Law 230 of August 26, 2004, as amended). This study was also supported by competitive grants from the Spanish Ministry of Science, Innovation, and Universities (PGC2018-097019-B-I00), and the Carlos III Institute of Health-Fondo de Investigación Sanitaria grant PRB3 (IPT17/0019—ISCIII-SGEFI / ERDF, ProteoRed). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MCIU), and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). The content is entirely the responsibility of the authors and does not necessarily represent the official views of the NIH nor of the Comprehensive Cancer Center UPR. Infrastructure support was provided in part by the National Institute on Minority Health and Health Disparities RCMI Grant: U54MD007600 and the Comprehensive Cancer Center—Clinical Proteomics Laboratory and RCMI Proteomics CORE in San Juan, Puerto Rico, for research facilities and technical support.

ACKNOWLEDGMENTS

We acknowledge the staff administration and the nursing and surgery teams of Hospital HIMA San Pablo in Caguas, Puerto Rico, for the opportunity to collect human tissue samples used in this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2020.586287/full#supplementary-material
REFERENCES

1. Baskin LS. Hypospadias and genital development. In: Advances in Experimental Medicine and Biology. New York, NY: Kluwer Academic/Plenum Publishers (2004).
2. Bergman JF, Loane M, Vrijheid M, Pierini A, Nijman RJ, Addor MC, et al. Epidemiology of hypospadias in Europe: a registry-based study. World J Urol. (2015) 33:2159–67. doi: 10.1007/s00345-015-1507-6
3. Loane M, Dolk H, Kelly A, Teljeur C, Greenlee R, Denson J. Paper 4: EUROCAT statistical monitoring: identification and investigation of ten year trends of congenital anomalies in Europe. Birth Defects Res Part A Clin Mol Teratol. (2011) 91:331–43. doi: 10.1002/bdra.20778
4. Mai CT, Isenburg J, Langlois PH, Alverson CJ, Gilboa SM, Rickard R, et al. Population-based birth defects data in the United States, 2008 to 2012: Presentation of state-specific data and descriptive brief on variability of prevalence. Birth Defects Res Part A Clin Mol Teratol. (2015) 103:97–93. doi: 10.1002/bdra.23461
5. Paulouzo LJ, Erickson JD, Jackson RJ. Hypospadias trends in two US surveillance systems. Pediatrics. (1997) 100:831–4. doi: 10.1542/peds.100.5.831
6. Toppari J, Kaleva M, Virtanen HE. Trends in the incidence of cryptorchidism and hypospadias, and methodological limitations of registry-based data. Hum Reprod Update. (2001) 7:282–6. doi: 10.1093/humupd/7.3.282
7. Yu X, Narras N, Mastroiacovo P, Canfield M, Groisman B, Bermejo-Sánchez E, et al. Hypospadias prevalence and trends in international birth defect surveillance systems. 1980–2010. Eur Urol. (2019) 76:482–90. doi: 10.1016/j.euro.2019.06.027
8. Baskin LS, Ebbets MB. Hypospadias: anatomy, etiology, and technique. J Pediatr Surg. (2004) 41:663–72. doi: 10.1016/j.jpedsurg.2005.11.059
9. Carmichael SL, Shaw GM, Nelson V, Selvin S, Torfs CP, Curry CJ. Hypospadias in California: trends and descriptive epidemiology. Epidemiology. (2003) 14:701–6. doi: 10.1093/epi00.00116.435331.doi
10. Dolk H, Vrijheid M, Scott JE, Addor MC, Bottig B, de Vigan C, et al. Toward the effective surveillance of hypospadias. Environ Health Perspect. (2004) 112:398–402. doi: 10.1289/ehp.6398
11. Narras N, Bower C, Barker A. Increasing prevalence of hypospadias in Western Australia, 1980-2000. Arch Dis Child. (2007) 92:580–4. doi: 10.1136/adc.2006.112862
12. Beleza-Meireles A, Töhönen V, Söderhäll C, Schwentner C, Radmayr C, Kockum I, et al. Activating transcription factor 3: a hormone responsive gene in the etiology of hypospadias. Eur J Endocrinol. (2008) 159:729–39. doi: 10.1530/EJE-07-0793
13. Carmichael SL, Witte JS, Ma C, Lammer EL, Shaw GM. Hypospadias and variants in genes related to sex hormone biosynthesis and metabolism. Andrology. (2014) 2:130–7. doi: 10.1038/androy.2013.165.x
14. Chen T, Li Q, Xu J, Ding K, Wang Y, Wang W, et al. Mutation screening of BMP4, BMP7, HOXA4 and HOXB6 genes in Chinese patients with hypospadias. Eur J Hum Genet. (2007) 15:23–8. doi: 10.1038/sj.ejhg.5201722
15. Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH. The genetic and environmental factors underlying hypospadias. Sex Dev. (2015) 9:239–59. doi: 10.1159/000441988
16. Haraguchi R, Mo R, Hui C, Motoyama J, Makino S, Shirioshi T, et al. Unique functions of Sonic hedgehog signaling during external genitalia development. Development. (2001) 128:4214–50.
17. Choudhry S, Baskin LS, Lammer EL, Witte JS, Dasgupta S, Ma C, et al. Genetic polymorphisms in ESR1 and ESR2 genes, and risk of hypospadias in a multiethnic study population. J Urol. (2015) 193:1625–31. doi: 10.1016/j.juro.2014.11.087
18. Geller F, Feenstra B, Carstensen L, Pers TH, van Rooij IA, Körberg IB, et al. Genome-wide association analyses identify variants in developmental genes associated with hypospadias. Nat Genet. (2014) 46:957–63. doi: 10.1038/ng.3063
19. Kalfa N, Philibert P, Sultan C. Is hypospadias a genetic, endocrine or environmental disease; or still an unexplained malformation? Int J Androl. (2009) 32:187–97. doi: 10.1111/j.1365-2605.2008.00899.x
20. Köhler B, Deleziole AL, Boizet-Bonhure B, McPhail MJ, Sultan C, Lumbroso S. Coexpression of Wnt1’s tumor suppressor 1 (WT1) and androgen receptor (AR) in the genital tract of human male embryos and regulat
81. Yin Y, Lin C, Kim ST, Roig I, Chen H, Liu L, et al. (2011). The E3 ubiquitin ligase Cullin 4A regulates meiotic progression in mouse spermatogenesis. *Dev Biol*. (2009) 356:51–62. doi: 10.1016/j.ydbio.2011.05.661

82. Zhang Q, Fillmore TL, Schepmoes AA, Clauss TR, Gritsenko MA, Mueller PW, et al. Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes. *J Exp Med*. (2013) 210:191–203. doi: 10.1084/jem.20111843

83. Kim SJ, Chae S, Kim H, Mun DG, Back S, Choi HY, et al. A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus. *Mol Cell Proteomics*. (2014) 13:811–22. doi: 10.1074/mcp.M113.035501

84. Schiller HB, Fernandez IE, Burgstaller G, Schaab C, Scheltema RA, Schwarzmayr T, et al. Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair. *Mol Syst Biol*. (2015) 11:819. doi: 10.15252/msb.20156123

85. Cunha GR, Liu G, Sinclair A, Cao M, Glickman S, Cooke PS, et al. Androgen-independent events in penile development in humans and animals. *Differentiation*. (2020) 111:98–114. doi: 10.1016/j.diff.2019.07.005

86. Boas M, Boisen KA, Virtanen HF, Kaleva M, Suomi AM, Schmidt IM, et al. Postnatal penile length and growth rate correlate to serum testosterone levels: a longitudinal study of 1962 normal boys. *Eur J Endocrinol*. (2006) 154:125–9. doi: 10.1530/eje.1.02066

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Piñeyro-Ruiz, Serrano, Jorge, Miranda-Valentin, Pérez-Brayfield, Camafeita, Mesa, Vázquez and Jorge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.